Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola

[Business Wire] – The Angola Sickle Cell Initiative, a public-private partnership of the Angola Ministry of Health, the Baylor College of Medicine International Pediatric AIDS Initiative , Texas Children’s Hospital and Chevron, is teaming up with the global biopharmaceutical company Bristol-Myers Squibb to provide children with sickle cell disease in Angola with an effective medication to which many patients in the … Read more on this. Bristol-Myers Squibb Company (BMY) , with a current market cap of $117.87B, started trading this morning at $70.75. During today’s session, BMY traded between $70.53 to $71.85 with the price of the stock fluctuating between $51.82 to $75.12 over the last 52 weeks. Bristol-Myers Squibb (BMY) shares are currently priced at 28.38x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 0.52x earnings multiple for the same period. And for income investors, the company pays shareholders $1.52 per share annually in dividends, yielding 2.14%. According to a consensus of 19 analysts, the earnings estimate of $0.66 per share would be $0.13 better than the year-ago quarter and a $0.04 sequential increase. What we find to be interesting is that the full-year EPS estimate of $2.56 is a $0.55 better when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $4.60 Billion. If realized, that would be a 10.58% increase over the year-ago quarter. Recently, Hilliard Lyons Initiated BMY at Neutral (May 23, 2016). Previously, Societe Generale Initiated BMY at to Sell. Given all the information above, we should disclose to readers that the average price target is $76.52, which is 8.16% above than it opened this morning. See more in (NYSE:BMY) Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents